The first is the capacity of Everolimus to restrain the progression of skeletal metastatic disease in BC patients through a specific mechanism that includes inhibiting the release by these cells of the most effective pro-OC factors such as M-CSF, TNFα, IL-1β, IL-6, MIP-1α and MMP-13. This evidence concerns the gene TNF and breast cancer.